Roberts Pharmaceutical started trading on the American Stock Exchangelast month under the symbol RPC. The company said that the move from the dealer-oriented, over-the-counter market to the public auction market of AMEX is expected to provide benefits to shareholders, such as a narrowing of the spread between bid and ask prices, reduced volatility, enhanced liquidity and greater visibility.
The company has launched two products from its own pipeline, Proamatine (midodrine HCL; Marketletter May 19) and Agrylin (anagrelide HCl; Marketletter March 24), and said it is "on a threshold of an exciting new phase in its growth cycle."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze